Bupa UK to cover EpiSwitch庐 CiRT for customers with cancer

TAGGED : medication

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

October 27, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 27, 2023--<a ...

Otsuka Pharmaceutical Announces Positive Topline Results From Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

October 27, 2023

TOKYO & PRINCETON, N.J.--(BUSINESS WIRE)--Oct 27, 2023--Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the ...

2% of kids and 7% of adults have gotten the new COVID shots, US data show

October 26, 2023

NEW YORK (AP) 鈥� A month after federal officials <a href="https://apnews.com/article/covid-vaccines-shots-cdc-5bc4db844557120bcc50dc0838c0e044">recommended new versions</a> of COVID-19 vaccines, 7% of U.S. adults and 2% of children have gotten a shot.One expert ...

Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

October 26, 2023

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Oct 26, 2023--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) 鈥� Aurinia welcomes the 2023 updated recommendations from The European Alliance of Associations for Rheumatology (EULAR) for the management of ...

Global Ophthalmic Packaging Market Set to Reach $20.3 Billion by 2030, Fueled by Strong 8.4% CAGR – ResearchAndMarkets.com

October 26, 2023

DUBLIN--(BUSINESS WIRE)--Oct 26, 2023--The <a ...

BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly蘑菇视频 Chorus Organization

October 26, 2023

RICHMOND, Calif.--(BUSINESS WIRE)--Oct 26, 2023--BioAge Labs, Inc., (鈥淏ioAge鈥�), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced plans to initiate a Phase 2 trial of its oral apelin ...